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clopidogrel after hospitalization for acute
coronary syndrome
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Background: Chronic kidney disease (CKD) is associated with worse outcomes among patients with acute coronary
syndrome (ACS). Less is known about the impact of CKD on longitudinal outcomes among clopidogrel treated
patients following ACS.
Methods: Using a retrospective cohort design, we identified patients hospitalized with ACS between 10/1/2005
and 1/10/10 at Department of Veterans Affairs (VA) facilities and who were discharged on clopidogrel. Using
outpatient serum creatinine values, estimated glomerular filtration rate [eGFR (1.73 ml/min/m2)] was calculated
using the CKD-EPI equation. The association between eGFR and mortality, hospitalization for acute myocardial
infarction (AMI), and major bleeding were examined using Cox proportional hazards models.
Results: Among 7413 patients hospitalized with ACS and discharged taking clopidogrel, 34.5% had eGFR 30–60
and 11.6% had eGFR < 30. During 1-year follow-up after hospital discharge, 10% of the cohort died, 18% were
hospitalized for AMI, and 4% had a major bleeding event. Compared to those with eGFR > =60, individuals with
eGFR 30–60 (HR 1.45; 95% CI: 1.18-1.76) and < 30 (HR 2.48; 95% CI: 1.97-3.13) had a significantly higher risk of death.
A progressive increased risk of AMI hospitalization was associated with declining eGFR: HR 1.20; 95% CI: 1.04-1.37 for
eGFR 30–60 and HR 1.47; 95% CI: 1.22-1.78 for eGFR < 30. eGFR < 30 was independently associated with over a
2-fold increased risk in major bleeding (HR 2.09; 95% CI: 1.40-3.12) compared with eGFR > = 60.
Conclusion: Lower levels of kidney function were associated with higher rates of death, AMI hospitalization, and
major bleeding among patients taking clopidogrel after hospitalization for ACS.
Keywords: Kidney disease, Myocardial infarction, Hospitalization, BleedingBackground
Approximately 30% to 50% of patients with acute coro-
nary syndrome (ACS) have evidence of chronic kidney
disease (CKD) [1,2]. Patients with CKD have worse out-
comes (i.e., recurrent adverse cardiac events, longer
hospitalization, and increased mortality) following ACS
regardless of treatment strategy, percutaneous coronary
intervention (PCI) or medical therapy [3-14]. While* Correspondence: fischerm@uic.edu
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reproduction in any medium, provided the orclopidogrel has been shown to reduce vascular related
mortality and cardiovascular (CV) events in high-risk
populations by inhibiting intravascular thrombosis
[15,16], post-hoc subgroup analyses of two clinical trials
demonstrated that clopidogrel has a less beneficial effect
on reducing the risk of cardiovascular events for adults
with CKD [17,18].
A number of reasons may explain the worse outcomes
associated with CKD, including more complex coronary
anatomy, a greater atherosclerotic burden, an underlying
prothrombotic state, and decrease platelet responsive-
ness to antiplatelet agents in the setting of CKD [19-25].
A few observational studies examining outcomes amongLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dogrel following PCI found that the presence of CKD was
associated with adverse ischemic events and bleeding
[26-28]. However, these studies were limited because they
did not account for differences in clopidogrel treatment
duration, did not include patients treated medically with-
out PCI for ACS, or had a paucity of patients with severe
CKD, all of which have important implications for out-
comes [26-28].
In order to improve our understanding of the impact
of CKD in adults treated with clopidogrel after ACS, our
objective was to examine the relationship between levels
of kidney function and a range of outcomes, namely
mortality, recurrent myocardial infarction, and bleeding,
in a large national cohort of elderly patients hospitalized
for ACS. Specifically, we address limitations of the prior
literature because our cohort includes patients with a
broad range of kidney function, even those with severe
CKD, patient treated both medically and with PCI for
ACS, and data on clopidogrel treatment duration during
follow-up. We hypothesized that lower levels of kidney
function would be associated with increased rates of
death, hospitalization, and bleeding in this clopidogrel-
treated cohort following ACS.
Methods
Design and study sample
Using a retrospective cohort study design, data for this
study were collected as part of the Department of
Veterans Affairs (VA) Veterans Health Administration
Cardiac Care Follow-up Clinical Study, which has been
described in detail elsewhere [29,30]. Briefly, the records
of all patients with ACS, as defined by acute myocardial
infarction (AMI) and a random sample of all patients
with unstable angina (UA), discharged from a VA hos-
pital were abstracted as part of a national VA cardiac
care initiative. All patients with International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9CM) diagnosis codes 410.xx (acute myocardial
infarction) and 411.xx (other acute and subacute forms
of ischemic heart disease) were identified from the VA
Patient Treatment File, and their records were manually
abstracted by trained abstractors using standard repor-
ting forms. Additional details of the study methods have
been published [31].
Based on the above criteria, the study cohort included
22,948 patients who presented to a VA facility between
October 1, 2005, and January 10, 2010 with an ACS. We
included all patients who were admitted and hospita-
lized, survived to hospital discharge, and were prescribed
clopidogrel at time of discharge. We excluded 8,757
patients who received palliative care, had decisions not
to treat, or received same day discharge or non-routine
discharges (i.e., transfers), 4,952 were excluded who didnot receive clopidogrel at discharge, and an additional
1826 were excluded who lacked an eGFR value. Hence,
our final analytic study cohort was 7,413.
Variables and data sources
Clopidogrel use was assessed using the Veterans Health
Administration Pharmacy Benefits Management data-
base, which records the date dispensed and the number
of days supplied for each dispensed medication. Du-
ration of clopidogrel therapy was calculated from the
day of hospital discharge to the last clopidogrel refill
date plus the number of days supplied for that last refill
[32,33]. When there was a gap of more than 7 days bet-
ween prescription refills, patients were considered to
have discontinued the medication. The presence of other
medications at discharge was also assessed from VA
external peer review program (EPRP) chart review.
Glomerular filtration rate (eGFR, ml/min/1.73 m2) was
calculated by the four-variable CKD-EPI estimating
equation, and patients were classified by strata of eGFR
consistent with current guidelines [34]. Other comorbid
health conditions during hospitalization were identified
by ICD-9CM codes. Data regarding PCI, stent placement
and type, and thrombolysis in myocardial infarction
(TIMI) score were also recorded.
Outcomes and data sources
The primary outcomes were: i) all-cause mortality ii)
readmission/hospitalization for AMI, iii) a combined
measure of all-cause mortality or readmission/hospi-
talization for AMI, and iv) major bleeding. Death was
ascertained in the VA Vital Status File [35,36]. The re-
admission/re-hospitalization AMI outcome was based
on a primary discharge International Classification of
Diseases, Ninth Revision, Clinical Modification diagnosis
code of 410.XX for any hospitalization within the VA.
Major bleeding events were defined by either i) a
hospitalization with a primary ICD-9 CM code for
bleeding [430.xx (subarachnoid hemorrhage), 431.xx (in-
tracerebral hemorrhage), 432.xx (other and unspecified
intracranial hemorrhage), 578.xx (gastrointestinal
hemorrhage) 719.1x (hemarthrosis), 423.0x (hemoperi-
cardium), 599.7x (hematuria), 626.2x (excessive or
frequent menstruation), 626.6x (metrorrhagia), 626.8x
(other gynecologic bleeding), 627.0x (premenopausal
menorrhagia), 627.1x (postmenopausal bleeding), 786.3x
(hemoptysis), 784.7x (epistaxis), 459.0x (hemorrhage
NOS)] OR ii) a secondary ICD-9 CM code for bleeding
and blood transfusion (99.0x).
Statistical analyses
Patient characteristics at entry into the cohort were
described overall and by eGFR strata using mean +/−
standard deviation (SD) for quantitative variables and
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analyses involving ANOVA and Chi-square tests were
used as appropriate to assess differences in patient
characteristics.
Corresponding Kaplan-Meier curves were constructed
to display the cumulative incidence of these four events.
In computations of event rates and in Cox regression
analyses, follow-up time was censored at discontinuation
of clopidogrel use or lost to follow up. All cause death
was ascertained until the administrative end date of the
study.
Cox proportional hazards regression models were
used to assess the association between each of these
four outcomes and eGFR strata (defined at hospital dis-
charge) among all participants who received clopidogrel
at hospital discharge. The assumption of proportional
hazards in the Cox regression models was checked
using Schoenfeld residuals for all included covariates.
Variables that did not meet the assumptions where
stratified before including them in the model.
All analyses were conducted using Stata version 9.0
(StataCorp, College Station, Texas). The Cardiac Care
Follow-up Clinical Study was approved by the University
of Washington’s human subjects committee and VA
Institutional Review Board.
Results
Study sample and characteristics
Among the 7413 individuals in the final analytic cohort, the
majority was male (98%), white (80%), and elderly (mean
age 66 years) (Table 1). The cohort was distributed by eGFR
levels as follows: 53.9% with eGFR > = 60 1.73 ml/min/m2,
34.5% with eGFR 30–60 1.73 ml/min/m2, and 11.6% with
eGFR < 30 1.73 ml/min/m2. A large proportion of the
cohort had chronic medical conditions, especially hyperlip-
idemia (76%), diabetes (42%), and hypertension (28%).
Fifty-nine percent of the cohort had a TIMI score > = 3 and
22% had a left ventricular ejection fraction (LVEF) < 40%.
While 42% did not have a percutaneous coronary inter-
vention (PCI) during hospitalization, 45% had a PCI with
a drug eluting stent (DES) and 13% had a PCI with a bare
metal stent (BMS).
A progressive increase in mean age and frequency
of non-white race was observed with lower strata of
eGFR (p < 0.001). The majority of comorbid conditions
(e.g., diabetes, hypertension, stroke, peripheral vascular
disease, and history of myocardial infarction) were sig-
nificantly more prevalent among individuals with lower
eGFR strata <60 than in those with higher eGFR > =60
(p < 0.001). While beta-blocker use at discharge was
similar across strata of eGFR, ACE-I use was signi-
ficantly less frequent in those with lower eGFR (<60)
(p < 0.001). LVEF < 40% and a TIMI score > = 3 was
progressively greater in individuals with lower eGFR(p < 0.001). The proportion of individuals receiving
PCI steadily decreased with lower eGFR (69% with
eGFR > 60; 34% with eGFR < 30) (p < 0.001). Similarly,
PCI with DES, and PCI with BMS was progressively
lower in those with lower eGFR (p < 0.001).
Duration of clopidogrel use
Duration of clopidogrel use following hospital discharge
was progressively shorter with lower eGFR level among
patients with or without PCI (p < 0.01) Table 2. Among
those without PCI, mean (SD) days of clopidogrel use
was 241 (130) in individuals with eGFR > =60 and 209
(130) in individuals with eGFR < 30, while among those
with PCI, mean (SD) days of clopidogrel use was 297
(105) and 259 (126) in those with eGFR > =60 and < 30,
respectively.
Clinical outcomes by eGFR strata
During 1 year of follow up after hospital discharge, 10%
of the cohort died, 18% had a hospitalization for AMI,
25% either died or had a hospitalization for AMI, and
4% had a major bleeding event. The cumulative inci-
dence of each of these outcomes was progressively
higher for lower strata of eGFR (Figure 1A-D). While 5%
of patients with an eGFR > =60 died, 12% of those with
an eGFR 30–60 and 28% of those with an eGFR < 30
died during follow up (p < 0.001). Similarly, only 14% of
individuals with an eGFR > = 60 had a hospitalization for
AMI, which contrasted with the 21% of those with an
eGFR 30–60 and 27% with an eGFR < 30 who required
hospitalization for AMI (p < 0.001). Lastly, although a
major bleeding event occurred among 3% of patients
with an eGFR > = 60, such events happened in 5% of
those with an eGFR 30–60 and 10% of those with an
eGFR < 30 (p < .001).
Association between eGFR and clinical outcomes
In regression analyses adjusted for several demographic
characteristics, medications, and clinical factors, low
eGFR was significantly associated with an increased risk
for each of the outcome measures (Table 3). Compared
to those with an eGFR > =60, individuals with an eGFR
30–60 and < 30 had nearly 1.5 fold higher (HR 1.45; 95%
CI: 1.18-1.76) and 2.5 fold higher (HR 2.48; 95% CI:
1.97-3.13) risk of death, respectively. Similarly, a pro-
gressive increased risk of hospitalization for AMI was
associated with declining eGFR, HR 1.20; 95% CI: 1.04-
1.37 and HR 1.47; 95% CI: 1.22-1.78 for eGFR 30–60
and < 30, respectively. Also, an increased risk for the
composite outcome of death or hospitalization for AMI
was observed with eGFR 30–60 (HR 1.22; 95% CI: 1.08-
1.37) and eGFR < 30 (HR 1.77; 95% CI: 1.52-2.06) com-
pared with an eGFR > = 60. Compared with the highest
strata eGFR (> = 60), while eGFR 30–60 was not asso-
Table 2 Days of clopidogrel use during 1 year after hospital discharge by presence of PCI and eGFR strata
No PCI PCI
N Mean days SD p-value* N Mean days SD p-value*
eGFR level <0.01 <0.01
> = 60 1215 241 130 2782 297 105
30-60 1208 232 132 1351 293 110
<30 567 209 130 290 259 126
*comparison among three levels of eGFR.







eGFR < 30 ml/min/m2
(n = 857)
p-value
Age (mean +/− SD) 66.3 (11.2) 61.9 (9.9) 71.2 (10.5) 71.9 (10.5) <0.001
Male sex (%, n) 98 (7294) 98 (3936) 98 (2513) 99 (845) 0.61
White race (%, n) 80 (5963) 82 (3269) 81 (2083) 71 (611) <0.001
Medical conditions (%, n)
Diabetes 42 (3139) 35 (1385) 47 (1209) 64 (545) <0.001
Hypertension 28 (2101) 21 (843) 33 (840) 49 (418) <0.001
H/o MI 19 (1410) 17 (692) 21 (544) 20 (174) <0.001
CHF 13 (999) 6 (227) 18 (453) 37 (319) <0.001
Stroke 2 (172) 2 (65) 3 (75) 4 (32) <0.001
PAD 13 (974) 10 (398) 15 (395) 21 (181) <0.001
Lipid disorder 76 (5627) 77 (3070) 77 (1976) 68 (581) <0.001
Liver disease 2 (177) 3 (108) 2 (50) 2 (19) 0.15
COPD 12 (902) 11 (439) 14 (355) 13 (108) .002
Cancer 5 (388) 5 (182) 6 (155) 6 (51) .017
Dementia 4 (309) 4 (152) 5 (119) 4 (38) 0.226
Depression 9 (642) 10 (399) 8 (196) 5 (47) <0.001
Current smoker (%, n) 31 (2333) 42 (1681) 21 (537) 13 (115) <0.001
LVEF (%, n) <0.001
EF > = 40% 73 (5430) 78 (3121) 70 (1786) 61 (523)
EF < 40% 22 (1622) 16 (630) 27 (688) 35 (304)
missing 5 (361) 6 (246) 3 (85) 4 (30)
Procedure (%, n) <0.001
No PCI 41 (2990) 31 (1215) 47 (1208) 66 (567)
PCI/no stent 2 (175) 3 (109) 2 (47) 2 (19)
PCI/BMS 13 (929) 14 (540) 12 (311) 9 (78)
PCI/DES 45 (3287) 53 (2111) 39 (984) 22 (192)
TIMI > = 3 (%, n) 59 (4371) 48 (1901) 71 (1821) 76 (649) <0.001
Glycoprotein inhibitor (%, n) 46 (3394) 53 (2130) 41 (1059) 24 (205)
Hospital discharge medications (%, n)
ASA 95 (7016) 96 (3821) 94 (2404) 92 (791) <0.001
Beta-blocker 93 (6925) 94 (3752) 93 (2375) 93 (798) 0.223
ACE-I 71 (5276) 77 (3068) 70 (1799) 48 (409) <0.001
ARB 9 (644) 6 (256) 11 (280) 13 (108) <0.001
heparin 4 (264) 4 (142) 4 (100) 3 (22) 0.186
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Figure 1 Cumulative Incidence of Outcomes by eGFR Strata (ml/min/1.73m2). A: Cumulative Incidence of All-cause Death by eGFR Strata
(ml/min/1.73 m2). B: Cumulative Incidence of Readmission/Hospitalization for Acute Myocardial Infarction by eGFR Strata (ml/min/1.73 m2).
C: Cumulative Incidence of All-cause Death or Readmission/Hospitalization for Acute Myocardial Infarction by eGFR Strata (ml/min/1.73 m2).
D: Cumulative Incidence of Major Bleeding by eGFR Strata (ml/min/1.73 m2).
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ding (HR 1.10; 95% CI: 0.80-1.53), the lowest strata of
eGFR (<30) was independently associated with over a
2 fold increased risk in major bleeding (HR 2.09; 95%
CI: 1.40-3.12).
Discussion
In a large national cohort of elderly patients hospitalized
with ACS and prescribed clopidogrel at discharge, moder-
ate and severe CKD were associated with a greater risk of
several unfavorable clinical outcomes and complications.
A graded increased risk of all cause mortality and hos-
pitalization for AMI was observed with lower levels of
eGFR, including nearly a 2.5- and 1.5-fold increased risk
with eGFR < 30, respectively. Over a 2-fold increased risk
of major bleeding events was associated with eGFR < 30.
In addition, a progressively shorter duration of outpatient
clopidogrel therapy after hospital discharge was observed
with lower levels of eGFR, regardless of whether PCI was
performed. Among patients with PCI, patients with eGFR< 30 had taken clopidogrel 13% fewer days than those with
eGFR > = 60 during follow up.
Several studies of ACS have demonstrated a negative
relationship between CKD, recurrent MI, and survival
[3-10]. Two post-hoc analyses of clinical trials compa-
ring clopidogrel to placebo found that CKD (eGFR < 60)
was associated with an increased risk of a composite
outcome MI, CV death or stroke [17,18]. Observational
studies of clopidogrel use post PCI have noted higher
rates of stent restenosis, myocardial infarction and death
in patients with low kidney function compared to those
with normal kidney function [26-28]. However, these
studies have important limitations such as including few
patients with severe CKD, unaccounting of clopidogrel
treatment duration, comprising single center cohorts,
utilizing inferior methods of estimating kidney function,
and failing to include patients without PCI [26-28].
In contrast to these prior reports, we included both
patients with and without PCI, and robustly examined
patients with very low eGFR (< 30), finding them to be
Table 3 Association between eGFR and clinical outcomes
among patients using clopidogrel*
eGFR strata Adjusted HR (95% CI)
All cause mortality
> = 60 1.0 (ref)
60 - 30 1.45 (1.18-1.76)
< 30 2.48 (1.97-3.13)
Readmission/hospitalization for AMI
> = 60 1.0 (ref)
60 - 30 1.20 (1.04-1.37)
< 30 1.47 (1.22-1.78)
All cause mortality or readmission/hospitalization for AMI
> = 60 1.0 (ref)
60 - 30 1.22 (1.08-1.37)
< 30 1.77 (1.52-2.06)
Major bleeding
> = 60 1.0 (ref)
60 - 30 1.10 (0.80-1.53)
< 30 2.09 (1.40-3.12)
*adjusted for age, sex, race, comorbid conditions (Table 1), smoking, medications
(Table 1), PCI/stent, LVEF, TIMI score.
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reasons likely underlie the marked association between
severe CKD and poor outcomes, including a greater
number of cardiovascular risk factors, more complex
coronary anatomy, increased overall atherosclerotic dis-
ease burden, and lower frequency of PCI and other
recommended ACS treatments during hospitalization
and follow up in patients with CKD [26-28]. Patients
with CKD have been shown to have a greater risk of
thrombotic complications including stent thrombosis
[6,37], and it has been posited that a prothrombotic state
may exist in CKD as evidenced by increases in fibri-
nogen, vonWillebrand’s factors, and decreases in anti-
thrombin III [22,23].
Many types of cardioprotective medications and other
evidence-based treatments are underutilized in adults
with CKD and cardiac risk factors or ACS [38-42]. Simi-
lar to our observations of a shorter duration of clopi-
dogrel use in patients with lower eGFR after ACS, a
multicenter study of patients undergoing PCI and stent
placement noted that as creatinine clearance declined,
there was a decrease in the percent of patients taking
clopidogrel at 1 year post-procedure [28]. A one year
prospective study of 1622 adults prescribed antiplatelet
therapy after drug-eluting stent placement observed that
14% interrupted at least one antiplatelet drug during this
time, including 11.8% who stopped clopidogrel [43].
Renal impairment was associated with nearly a 3 fold in-
creased odds of discontinuation of antiplatelet drugs
[43]. Reasons for shorter duration of antiplatelet therapyand discontinuation observed in these studies and ours
may include bleeding events, scheduled invasive pro-
cedures, psychiatric drug use, unemployment, patient
choice and non-adherence, and other medical events not
specified including earlier mortality [43].
Concern for antiplatelet therapy-related bleeding
events may curtail provider treatment of patients with
CKD following ACS with these medications [28]. Others
have observed a progressive increase in both minor and
major bleeding events with lower levels of kidney func-
tion for patients during hospitalization for ACS [28] or
in the course of follow up thereafter while on anti-
platelet therapies [17,18,27]. Fewer have demonstrated
an independent relationship between low levels of kid-
ney function and bleeding. While a prior study found an
independent relationship between creatinine clearance
(CrCl) < 30 ml/min and in-hospital bleeding events [28],
we observed a strong independent relationship between
eGFR < 30 and an increased risk of major bleeding
events after hospital discharge. Platelets are known to be
dysfunctional in the setting of CKD because of intrinsic
platelet abnormalities and impaired platelet-vessel wall
interactions, which may account for the increased risk of
bleeding in patients with CKD [18-23,44].
While this study leveraged a large national cohort with
varying degrees of CKD, meticulous data collection, and
outcome ascertainment, it does have limitations. First,
because this study has an observational study design, it
is subject to residual confounding and its results do not
indicate causality [45]. Furthermore, because this study
lacked a comparison group, it is not possible to make
conclusions regarding the risks and benefits of using
clopidogrel versus no clopidogrel in the CKD population
from this study. Nevertheless, it should be noted that
longitudinal studies are appropriate to robustly assess
epidemiologic relationships [45]. Second, because this
cohort consists exclusively of patients hospitalized at VA
facilities, its findings may not be generalizable to popula-
tions elsewhere. However, elderly male Veterans are a
vulnerable high-risk group that is subject to health dis-
parities and critically important to study [46]. Third, we
calculated eGFR and classified CKD based on a single
outpatient serum creatinine value. Similarly, we assigned
comorbid conditions based on a single ICD-9 code being
present in administrative data sources. Although this ap-
proach is acceptable in clinical and research settings,
some misclassification with comorbidity assignment and
CKD staging is possible. Fourth, we did not have data
regarding clopidogrel dose, but it does not appear to
significantly impact clinical outcomes [47]. Similarly,
while we employed meticulous medication data collec-
tion throughout hospitalization and follow up, there may
be medications not accounted for that may alter the effi-
cacy and risk profile of clopidogrel [48-50].
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In summary, among patients hospitalized with ACS and
treated with clopidogrel, lower levels of kidney function
were associated with a greater risk of death, hospita-
lization for AMI, and major bleeding. These findings
should remind clinicians of the increased risks for ad-
verse outcomes in their CKD patients following ACS
who are treated with clopidogrel. Further studies are
needed in order to provide sound evidence-based deci-
sion making for management decisions in this high-risk
group following ACS.
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